Navigation Links
NYSCF scientists develop new protocol to ready induced pluripotent stem cell clinical application
Date:4/3/2013

NEW YORK, NY (April 3, 2013) A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors. Reported in PLOS ONE, this cell-sorting method consistently selects the highest quality, standardized iPS cells, representing a major step forward for drug discovery and the development of cell therapies.

Employing a breakthrough method developed by 2012 Nobel laureate Shinya Yamanaka, MD, PhD, adult cells are "reprogrammed" or reverted to an embryonic-like state, commonly through viral infection. Reprogramming is a dynamic process, resulting in a mixture of fully reprogrammed iPS cells, partially reprogrammed cells, and residual adult cells. Previous protocols to select promising fully reprogrammed cells rely primarily on judging stem cell colonies by eye through a microscope.

Cell colonies selected by qualitative measures could include partially reprogrammed cells, a major concern for clinical applications of cell therapies because these cells could become any other cell type in a patient following transplantation. Additionally for drug efficacy assays and toxicity investigations on iPS cells, heterogeneous cell populations can mar the response of representative iPS cell lines.

The NYSCF scientists developed a quantitative protocol, optimized over three and a half years, in order to consistently harvest early-reprogrammed cells. Using fluorescence activated cell sorting (FACS), fully reprogrammed cells were identified by two specific proteins, or pluripotency markers. The group then looked at third marker that is expressed by partially reprogrammed or adult cells, and they then negatively selected against these cells to obtain only fully reprogrammed cells.

"To date, this protocol has enabled our group to derive (and characterize over) 228 individual iPS cell lines, representing one of the largest collections derived in a single lab," said Dr. Kahler. "This standardized method means that these iPS cells can be compared to one another, an essential step for the use in drug screens and the development of cell therapies."

This process of selecting stem cell colonies provides the basis for a new technology developed by NYSCF, The NYSCF Global Stem Cell Array (Array), a fully automated, robotic platform to generate cell lines in parallel. Currently underway at the NYSCF Laboratory, the Array reprograms thousands of healthy donors' and diseased patients' skin and/or blood samples into iPS cell lines. Sorting and characterizing cells at an early stage of reprogramming allows efficient development of iPS cell clones and derivation of adult cell types.

"We are enthusiastic about the promise this protocol holds to the field. As stem cells move towards the clinic, Dr. Kahler's work is a critical step to ensure safe, effective treatments for everyone," said Susan L. Solomon, CEO of NYSCF.


'/>"/>

Contact: David McKeon
dmckeon@nyscf.org
212-365-7440
New York Stem Cell Foundation
Source:Eurekalert

Related biology news :

1. NYSCF scientists develop 3-D stem cell culture technique to better understand Alzheimers disease
2. Scientists find government justification of new environmental policy unfounded
3. UGA discovery may allow scientists to make fuel from CO2 in the atmosphere
4. UT MD Anderson scientists uncover the nuclear life of actin
5. Scientists awarded £3M to study the way Northwest European seas absorb carbon
6. Scientists reveal quirky feature of Lyme disease bacteria
7. Scientists create new tools for battling secondhand smoke
8. Academy scientists receive top honors for long-term research and training initiatives in Mongolia
9. Scientists discover reasons behind snakes shrinking heads
10. U of T scientists map genome that causes Dutch Elm Disease
11. Scientists discover novel chemical that controls cell behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2020)... , ... August 19, 2020 , ... ... LLC and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than twenty ... recently published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 11, 2020 , ... ... R&D subsidiary based in Princeton, NJ, have entered into license agreements with Housey ... and development. Both Roche and J&J have annual Research and Development spending ...
(Date:8/7/2020)... ... August 06, 2020 , ... Nine middle school ... STEM Scholar Program, a unique professional development program that provides advanced STEM (science, ... school science teachers nationwide. , Created in partnership between the National Stem Cell ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... 08, 2020 , ... Bode Technology, a leading ... operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical ... provides a turnkey solution that includes a comprehensive collection and virus-management program ...
(Date:7/10/2020)... ... 09, 2020 , ... In most research using the zebrafish ... formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over the ... using the zebrafish model to investigate the causes of leukaemia and its relationship ...
(Date:7/7/2020)... ... , ... R3 International is now offering stem cell therapy for Alzheimers dementia ... on the patient's condition, treatment may be offered IV, intrathecal or with a combination. ... Alzheimers dementia, and the incidence continues to increase as individuals live longer. There is ...
(Date:7/1/2020)... CHARLOTTE, N.C. (PRWEB) , ... June 29, 2020 ... ... has reported year to date growth of 40% in 2020, despite many obstacles ... medical technology, MedShift aims to increase revenue for its partnered medical practices and ...
Breaking Biology Technology: